The ABHD4 Knockout Huh-7 Polyclonal Cells are a polyclonal knockout cell population generated by CRISPR/Cas9-mediated disruption of the human ABHD4 gene in the Huh-7 hepatocellular carcinoma cell line. This polyclonal pool offers a heterogeneous loss-of-function model suitable for studying ABHD4-dependent processes without clonal selection biases. The edited population can be used directly in functional assays or subjected to downstream enrichment strategies.
Huh-7 is a well-differentiated hepatocyte-derived cellular carcinoma cell line originally isolated from a liver tumor in a 57-year-old Japanese male. It is widely employed as a model for hepatocellular carcinoma (HCC), liver metabolism, and drug metabolism studies. Huh-7 cells retain many characteristics of primary hepatocytes, including expression of key metabolic enzymes and the ability to synthesize and secrete plasma proteins, making them a valuable system for investigating hepatic lipid handling and hepatotoxicity screening.
ABHD4 encodes an ??/??-hydrolase domain-containing lipase that hydrolyzes N-acyl-phosphatidylethanolamine (NAPE) to produce N-acylethanolamines (NAEs), including the endocannabinoid anandamide. This reaction is central to the N-acylethanolamine biosynthesis pathway and intersects with glycerophospholipid metabolism. ABHD4 functions downstream of NAPE-PLD and upstream of fatty acid amide hydrolase (FAAH) and other phospholipases. Anandamide generated by ABHD4 activates cannabinoid receptors, thereby modulating endocannabinoid signaling and lipid metabolism. The enzyme also exhibits activity toward lyso-phosphatidylserine, further implicating it in lysophospholipid metabolism. Potential upstream regulators include peroxisome proliferator-activated receptors (PPARs), linking ABHD4 to broader metabolic transcriptional networks.
In the context of Huh-7 hepatocellular carcinoma cells, ABHD4 disruption provides insights into the interplay between lipid metabolism and liver cancer biology. Given the liver??s central role in lipid processing and the dysregulation of endocannabinoid signaling in hepatic diseases, this knockout model enables detailed exploration of how NAE production influences hepatocellular carcinoma cell growth, survival, and metabolic reprogramming. Because Huh-7 cells are widely used in toxicology, ABHD4 knockout cells also serve as a platform to investigate the enzyme??s contribution to drug-induced lipid disturbances and hepatotoxicity.
Researchers can employ these polyclonal ABHD4 knockout Huh-7 cells in a range of experimental workflows, including LC?MS?based quantification of N?acylethanolamines, lipase activity measurements, western blotting, RT?qPCR, and global lipidomics. The cells are suitable for endocannabinoid system research, lipid metabolism studies, and liver cancer cell biology, as well as for screening pharmacological agents that target NAE?related pathways. The heterogeneous population can be challenged with lipid substrates, receptor agonists, or chemotherapeutic agents to assess functional outcomes in parallel with wild?type controls. For further details or technical support, please contact Ascent Research.
